ALFA Finder
India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold
Telegram alerts
alfafinder.com →
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
27 announcements
Medicamen Organics filed auditor certificate for Rs 87.5 lakh warrant balance received from Pradeep Kumar Jain. Warrant conversion allotted 10 lakh equity shares at Rs 35 each.
Medicamen Organics allotted 10,00,000 equity shares on conversion of warrants issued to Mr. Pradeep Kumar Jain. The company received the balance Rs.87.5 lakh, bringing total consideration to Rs.3.50 Crore.
Medicamen Organics held its 31st AGM on September 25, 2026. Shareholders approved audited financial statements, director reappointment, secretarial auditor appointment, and related party transactions.
Medicamen Organics Limited has re-appointed Ms. Divya Rani as the Secretarial Auditor of the company for a period of 12 months.
Medicamen Organics Limited informed shareholders about the web-link to access the Notice of the 31st AGM and Annual Report for FY 2025-26, as per regulatory compliance.
Medicamen Organics Ltd has scheduled its 31st Annual General Meeting for September 25, 2026. The board also approved the re-appointment of its Secretarial Auditors.
Mr. Brijesh Kumar Chaubey has resigned as Executive Director of Medicamen Organics Limited. The resignation is effective July 20, 2026, due to family medical issues.
Medicamen Organics Limited received Rs. 12.29 Crore in consideration for a preferential allotment of equity shares and warrants. The auditor certified compliance with SEBI ICDR Regulations.
Medicamen Organics allotted equity shares and warrants worth ₹13.65 Crore on a preferential basis. This capital infusion strengthens the company's equity base and supports future growth.
Medicamen Organics Limited amended its Code of Practices for Fair Disclosure of Unpublished Price Sensitive Information. This update ensures compliance with current SEBI regulations.
Medicamen Organics reported 15.41% unutilized IPO proceeds, totaling ₹162.44 Lakhs. Shareholders approved reallocating these funds from international product registration to meeting working capital requirements.
Medicamen Organics Ltd reported revenue from operations of ₹4.8 Cr (-77.8% YoY) and a net loss of ₹6.1 Cr for H2 FY26.
Medicamen Organics Limited reported its audited standalone and consolidated financial results for the year ended March 31, 2026. The Board approved the results at a meeting today.
Medicamen Organics Limited is undertaking a ₹13.65 Crore preferential issue of equity shares and warrants. The capital raise includes a loan conversion by a promoter.
Medicamen Organics Limited scheduled a board meeting for May 29, 2026, to approve audited annual financial results. The trading window remains closed until May 31, 2026.
Medicamen Organics published a valuation report from M/s Jhamb & Associates on its website. The report supports shareholder approval for matters in the upcoming Extra-ordinary General Meeting.
Medicamen Organics clarified potential re-computation of security prices for its ongoing preferential issue. Allotted securities will remain locked-in until any additional re-computed amounts are fully paid.
Medicamen Organics Limited submitted its Structured Digital Database compliance certificate for the financial year ended March 31, 2026. Issued by M/s KNGC and Associate LLP, the certificate confirms the company maintained records for 19 required events as per SEBI PIT Regulations.
Medicamen Organics Limited has appointed Ms. Divya Sharma as Company Secretary, effective April 17, 2026. Ms. Sharma is an Associate member of the ICSI with over a decade of experience in corporate governance and statutory compliance across the manufacturing and IT sectors.
Medicamen Organics Limited has updated its list of Key Managerial Personnel authorized to determine the materiality of events for disclosure under Regulation 30(5). The authorized personnel include Mr. Bal Kishan Gupta (MD), Mr. Lalit Gupta (CFO), and Ms. Divya Sharma (Company Secretary), following her appointment on April 17, 2026.
Medicamen Organics Limited has appointed Ms. Divya Sharma as Company Secretary and Compliance Officer, effective April 17, 2026. Ms. Sharma, an Associate Member of ICSI with over a decade of experience, succeeds the previous officer. The board approved the appointment based on the Nomination and Remuneration Committee's recommendation.
Medicamen Organics Limited announced the cessation of Varsha Bansal from her role as Company Secretary, effective April 16, 2026. This administrative change follows statutory disclosure requirements for key managerial personnel.
Ms. Varsha Bansal has resigned as the Company Secretary and Compliance Officer of Medicamen Organics Limited, effective April 16, 2026. The resignation was due to personal reasons. The company is in the process of identifying a suitable replacement for the Key Managerial Personnel role.
Medicamen Organics Limited informed the National Stock Exchange that it is not classified as a Large Corporate as of March 31, 2026. Consequently, SEBI-mandated disclosure and compliance requirements for fund raising via debt securities by Large Entities are not applicable to the company.
Medicamen Organics Limited clarified to the NSE that the recent share price increase is purely market-driven. The company confirmed it has disclosed all material price-sensitive information in compliance with SEBI regulations and has not withheld any significant data. This statement ensures transparency regarding unusual market movements.
Medicamen Organics Limited announced that all resolutions placed at its EGM on April 09, 2026, were passed with requisite majority. Key approvals include increasing authorized share capital, appointing an Executive Director, and preferential issuances of equity shares and convertible warrants to promoter and public categories. The results were confirmed by a Scrutinizer's Report.
Medicamen Organics Limited held an EGM on April 09, 2026, to approve several resolutions. Key items include increasing authorized share capital, appointing an Executive Director, and issuing 20,00,000 equity shares and 11,85,715 warrants on a preferential basis. Voting results will be disclosed separately.